ArticleInternational journal of Alzheimer's disease2010
Ceruloplasmin/Transferrin ratio changes in Alzheimer's disease.
Article in International journal of Alzheimer's disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Iron in Alzheimer's Disease: From Physiology to Disease Disabilities.Biomolecules · 2022Review
- Iron and Alzheimer's Disease: From Pathology to Imaging.Frontiers in human neuroscience · 2022Review
- Alteration of Iron Concentration in Alzheimer's Disease as a Possible Diagnostic Biomarker Unveiling Ferroptosis.International journal of molecular sciences · 2021Review
- Nerve Growth Factor-Based Therapy in Alzheimer's Disease and Age-Related Macular Degeneration.Frontiers in neuroscience · 2021Review
- Machine Learning Profiling of Alzheimer's Disease Patients Based on Current Cerebrospinal Fluid Markers and Iron Content in Biofluids.Frontiers in aging neuroscience · 2021Article
- Association of Plasma Transferrin With Cognitive Decline in Patients With Mild Cognitive Impairment and Alzheimer's Disease.Frontiers in aging neuroscience · 2020Article
- Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability.Frontiers in neuroscience · 2019Article
- Neurotoxicity Linked to Dysfunctional Metal Ion Homeostasis and Xenobiotic Metal Exposure: Redox Signaling and Oxidative Stress.Antioxidants & redox signaling · 2018Review
- Loss of CaFrontiers in molecular biosciences · 2018Article
- Serum Copper, Zinc, and Iron Levels in Patients with Alzheimer's Disease: A Meta-Analysis of Case-Control Studies.Frontiers in aging neuroscience · 2017Article
- The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII.Journal of thrombosis and haemostasis : JTH · 2016Article
- Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy.Metabolic brain disease · 2015Article
- Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in Alzheimer's disease and vascular dementia.Rejuvenation research · 2013Article
- Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment.Journal of Alzheimer's disease : JAD · 2012Article
- Ceruloplasmin and iron proteins in the serum of patients with Alzheimer's disease.Dementia and geriatric cognitive disorders extra · 2011Article
- Glutamate-mediated primary somatosensory cortex excitability correlated with circulating copper and ceruloplasmin.International journal of Alzheimer's disease · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The link between iron and Alzheimer's disease (AD) has been mainly investigated with a focus on the local accumulation of this metal in specific areas of the brain that are critical for AD. In the present study, we have instead looked at systemic variations of markers of iron metabolism. We measured serum levels of iron, ceruloplasmin, and transferrin and calculated the transferrin saturation and the ceruloplasmin to transferrin ratio (Cp/Tf). Cp/Tf and transferrin saturation increased in AD patients. Cp/Tf ratios also correlated positively with peroxide levels and negatively with serum iron concentrations. Elevated values of ceruloplasmin, peroxides, and Cp/Tf inversely correlated with MMSE scores. Isolated medial temporal lobe atrophy positively correlated with Cp/Tf and negatively with serum iron. All these findings indicate that the local iron accumulation found in brain areas critical for AD should be viewed in the frame of iron systemic alterations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.